The 5th China Healthcare Investment Conference (CHIC) was held on March 4-6, 2014 in Shanghai. Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics, was invited to speak at the conference and share TenNor’s product portfolio and development strategy. First held in 2010, CHIC was a joint effort by a group of world-class investors who had recognized that the healthcare reform and economic growth in China were spurring a new wave of emerging Chinese healthcare companies. Now in its 5th year, CHIC has established itself as the preeminent platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the biotechnology industry.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com